Redhill Biopharma
Update in progressRDHL (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
RedHill Biopharma Ltd. is a specialty biopharmaceutical company based in Tel Aviv-Yafo, Israel. It develops and markets GI and infectious-disease therapies, including Talicia for H. pylori and Aemcolo for travelers’ diarrhea in adults. Its pipeline features five candidates: opaganib for severe COVID-19 pneumonia; RHB-107 (upamostat) for outpatient SARS-CoV-2 infection and cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for acute gastroenteritis/IBS-D and anti-emetic use; and RHB-204 for pulmonary MAC disease.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationIsrael
- CEOMr. Dror Ben-Asher
- Founded2009
- Employees13
- Websitewww.redhillbio.com
Identifiers
- ISINUS7574681034
- FIGIBBG003RY91S7
- LEI52990034U7FZBKRAOE32
- CUSIP757468103
- CIK0001553846